Case Study: Sequencing Therapy in ES-SCLC in Special Patient Populations
Ticiana Leal, MD
Jacob Sands, MD
Case Study: Treatment Sequencing in Platinum-Resistant Relapse ES-SCLC
Case: Update of Neoadjuvant Therapies for Resectable Lung Cancer
Joshua E. Reuss, MD
Jessica S. Donington, MD, MSCR
Earlier Use of ICIs in NSCLC: Integrating the Latest Evidence Into Clinical Practice
MET Inhibition in Metastatic NSCLC “In the Spotlight”
Paul Paik, MD
D. Ross Camidge, MD, PhD
Keith Kerr, BSc, MB ChB
Expert Panel: How Does ADT Intensification for mHSPC Affect Future Therapy Options?
Alicia K. Morgans, MD, MPH
Kelvin A. Moses, MD, PhD, FACS
What Is the Pharmacist’s Role in Managing mHSPC Doublet and Triplet Regimens?
Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Expert Panel: Selecting Treatment in mHSPC: Which Treatment for Which Patient?
Expert Panel: How Can We Integrate Patient Preference Data To Support Shared Decision-Making Conversations in mHSPC?
How Nurses and Advanced Practice Clinicians Can Help Patients Navigate a New mHSPC Diagnosis
Stacy Walker, NP
What Can I Do to Improve Care of Prostate Cancer Patients at Risk for Inequities?
Choosing Between Doublets and Triplets in mHSPC: What Is the Data?
Intensifying ADT in mHSPC: How to Improve Patient Outcomes and Adherence
What Is the Current State of Disparities in Prostate Cancer Care?
Highlights from Madrid on Targeted Therapy for Advanced NSCLC
Charu Aggarwal, MD, MPH
Patrick Forde, M.B.B.Ch.
Highlights from Singapore on Targeted Therapies in NSCLC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.